by 
Blepharitis is a common eyelid condition characterized by redness, flaking, dryness and itching of the eyelids. If left untreated, it can worsen and lead to swelling of eyelids, eyelash loss and formation of crusts along the eyelid margin. Effective treatment options available in the market include ointments, warm compresses, eyelid scrubs and antibiotics that help clear out the bacteria and flakes on eyelids.
The global blepharitis treatment market is estimated to be valued at US$ 2.5 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the blepharitis treatment market are Scope Ophthalmic Ltd., NovaBay Pharmaceuticals Inc., Thea Pharmaceuticals Ltd., Perrigo Laboratories, InSite Vision Incorporated, Merck & Co., and Novartis AG. The key players are mainly focused on product innovation and development of generic drugs for effective blepharitis treatment.
The rising awareness about various treatment options for blepharitis condition and availability of generic drugs presents a huge growth opportunity for blepharitis treatment market players. The easy availability of over-the-counter products is expected to further propel the market growth during the forecast period.
Globally, there has been an increasing focus on expanding access to treatment of blepharitis, especially in emerging markets of Asia Pacific and Latin America. The key players are focused on these untapped markets by entering into partnerships with local pharmaceutical companies and lowering product prices.
Market drivers
Increasing prevalence of blepharitis across global population due to excessive screen time and growing geriatric population is expected to be a major driver for the blepharitis treatment market over the forecast period. According to several studies, blepharitis affects nearly 25% of worldwide population leading to increased diagnosis and treatment uptake. Moreover, the development of alternative treatment options such as ocular lubricants and lid scrubs in addition to antibiotics is further expected to boost the market growth during 2023-2030.
PEST Analysis
Political: Regulations regarding drug approvals can affect the blepharitis treatment market. Stringent regulations might slow down the market growth.
Economic: Rising healthcare spending and growing cases of blepharitis are increasing the demand for effective treatment options. This will drive the blepharitis treatment market.
Social: Growing awareness about eye care and availability of various treatment types are positively impacting the market. People are more receptive towards new treatments.
Technological: Advanced drug delivery methods and novel drug formulations are expanding treatment solutions. Researchers are working on new drugs and therapies to target underlying causes of blepharitis.
The blepharitis treatment market in terms of value is concentrated mainly in North America and Europe. These regions have established healthcare systems and eye care facilities. Availability of advanced treatment types and growing awareness levels are contributing to high market revenues in North America and Europe.
The Asia Pacific region is anticipated to be the fastest growing market for blepharitis treatment during the forecast period. This is attributed to rising healthcare expenditure, increasing cases of eye diseases, growing disposable incomes, expanding eye care services and growing medical tourism in countries like India and China. Other factors include rapid urbanization, large patient pool and growing awareness about various eye conditions including blepharitis.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
